Amgen v. Hospira Pegfilgrastim Case Stayed Pending Potential Summary Judgment Practice

Goodwin
Contact

Goodwin

On June 16, 2021, the District Court for the District of Delaware issued a claim construction order construing a key term in the ongoing patent dispute between Amgen and Hospira over Hospira’s proposed biosimilar of Amgen’s Neulasta® (pegfilgrastim).  In the Order, the Court construed the term “between about 0.1 M and about 1.0”  to have “its plain and ordinary meaning (that is, ‘between approximately 0.1 M and approximately 1.0 M’) and is not a functional limitation.”

After issuing the claim construction order, the Court also issued a second order that stayed the case “until a determination is made about whether the Court should entertain summary judgment practice on the issue of noninfringement.”  The Court further ordered that the parties shall jointly submit a status update by July 12, 2021.

The Parties previously indicated in a joint letter that the claim term “between about 0.1 M and about 1.0” is “central to the parties’ disputes” and potentially dispositive of the issue of infringement.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.